<DOC>
	<DOCNO>NCT00472953</DOCNO>
	<brief_summary>This trial conduct Europe , Asia South America . A one-year clinical trial compare safety inhale human insulin subcutaneous insulin aspart subject type 1 type 2 diabetes chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Safety Inhaled Human Insulin Subjects With Diabetes Mellitus Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>The decision discontinue development AERxÂ® due safety concern . An analysis conclude fast-acting inhaled insulin form know today , unlikely offer significant clinical convenience benefit injection modern insulin pen device .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Chronic Obstructive Pulmonary Disease Type 1 type 2 diabetes HbA1c low equal 11.0 % Body Mass Index ( BMI ) low equal 40.0 kg/m2 Recurrent severe hypoglycaemia Current smoking smoking within last 6 month Other pulmonary disease include asthma Proliferative retinopathy maculopathy require acute treatment</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>